Page results
-
UCLH is contributing to a national priority trial of the drug ruxolitinib in patients with Covid-19 pneumonia (infection of the lungs).
-
Initial results from an early phase study testing the safety and efficacy of a new drug for multiple myeloma have shown a 100 per cent overall response rate in patients with recurrent disease who were given the clinically recommended dose of the investigational drug.
-
This two-part workshop is specially created for teenagers seeking to understand their anxiety more deeply and discover practical, effective strategies to manage it.
-
The hospital marked the start of the year a visit by HM The Queen in February 2020. A few weeks after this celebration, the pandemic took hold and the hospital stepped up to help.
-
Specialist teams at UCLH and UCL are at the forefront of research which could bring hope to people who have been robbed of their sense of smell and taste after suffering the long-term legacy of COVID-19.
-
Learn more about how UCLH celebrated Research Open Day this month.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
This page tells you about the procedure known as a Bronchial Artery Embolisation (BAE).
File results
-
FOI2017266 Viscosupplementation injections
-
FOI2017263 Self-administration of medicines policies and carers policies
-
FOI2017295 A&E attendances for acopia
-
FOI2017296 Contracts for the redevelopment of the Middlesex annexe and Royal London Hospital for Integrated Medicine
-
FOI2017307 Televisions for patients
-
FOI2017314 Deep brain stimulation procedures
-
FOI2017300 Sustainability and transformation
-
FOI2017315 Expenditure on reconciliation and validation of incomplete and missing RTT codes
-
FOI2017320 Patients with Multiple Sclerosis treated with MS disease modifying drugs
-
FOI/2023/0226 - Treatment with Nivolumab